Heart attack and stroke medication recalled due to cancer-causing agent

Heart attack and stroke medication recalled due to cancer-causing agent
Top Stories
Quebec pharmaceutical company Pro Doc Limite has recalled two lots of a heart attack and stroke medication found to be contaminated with a cancer-causing impurity. (Pixabay/Pexels)

Jonathan Forani, Staff

Published Friday, March 15, 2019 10:57AM EDT

A Quebec pharmaceutical company has recalled two lots of a heart attack and stroke medication contaminated with a cancer-causing impurity.

Health Canada issued a statement Thursday advising Canadians that Laval-based Pro Doc Limite voluntarily recalled the lots of irbesartan tablets, which were only distributed in Quebec. Irbesartan is a sartan medicine used to treat patients with high blood pressure or those who have had heart failure or a recent heart attack.

There have been multiple recalls of products containing other sartans in Canada and internationally since July 2018 because of nitrosamine impurities, said Health Canada in the statement.

The nitrosamine impurity, N-nitrosodiethylamine (NDEA), found in the drugs is a probable human carcinogen, meaning the risk of cancer increases after long-term exposure.

Health Canada is advising that there is no immediate risk to patients taking these medications, since the potential risk of cancer is with long-term exposure to the impurities that exceed safe levels, said Health Canada. Patients should not stop taking their medication unless advised to do so by their health care provider.

The agency encouraged Canadians to visit the online database for more information on drugs that have been discontinued, adding that there are alternative products to the irbesartan tablets currently available on the Canadian market.

#RECALL : Do you take irbesartan medication? Pro Doc Limite is recalling two lots because of an impurity. The drugs were distributed only in #Quebec . Find out more: #sartan
Read more on CTVnews
News Topics :
Top Stories
Several companies are voluntarily recalling their drugs that treat high blood pressure because of a potential impurity that could increase the potential long term risk of cancer. The voluntary recall comes...
NMBA is considered a potential human carcinogen, meaning that long term exposure could potentially increase the risk of cancer. Apotex, Pharmascience and Pro Doc Limitée are also voluntarily recalling many of...
The drugs that contain valsartan manufactured by Zhejiang Huahai Pharmaceuticals, were the subject of recalls in July and August after an impurity, N nitrosodimethylamine NDMA was found. Now, Health Canada says...
A recall of medications used to treat high blood pressure and heart failure has been expanded over concerns additional lots of the drugs may contain a substance that can increase...
Health Canada announced the expanded recall on Sunday, after testing identified traces of the impurity in products from Teva Canada . Teva is among the top five Canadian pharmaceutical companies...